Dr Francesca Gay speaks to ecancer at the 2019 ASH meeting in Orlando about the use of multiparametric flow cytometry (MDC) and next generation sequencing (NGS) to characterise complete remission (CR) in patients with newly diagnosed multiple myeloma (NDMM) in the FORTE trial.
Dr Gay explains that these techniques displayed good concordance, as the rate of patients who achieve minimal residual disease (MRD) negativity were comparable between each arm. More specifically an 80 percent agreement was seen between each test.
She describes that these tests are extremely sensitive are in line with the current definition of MRD negativity and states the main advantages of each technique.
ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content